Skip to main content
Sprint Bioscience logo

Sprint Bioscience — Investor Relations & Filings

Ticker · SPRINT ISIN · SE0006343745 LEI · 5493006ED74WIIQOKC56 ST Professional, scientific and technical activities
Open in API
Filings indexed 1 across all filing types
Latest filing 2023-06-13 Regulatory Filings
Country SE Sweden
Listing ST SPRINT

About Sprint Bioscience

https://sprintbioscience.com/en/

Sprint Bioscience is a pharmaceutical company specializing in the early-stage development of innovative drug candidates for oncology. The company utilizes a fragment-based drug discovery (FBDD) platform to efficiently identify and advance small-molecule therapies targeting difficult-to-treat cancers. Its business model is centered on out-licensing these drug programs to global pharmaceutical companies during the preclinical phase for further development and commercialization.

Recent filings

Filing Released Lang Actions
Proventus Bioscience Breaks Ground in Quebec
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5822C' and contains language typical of a press release distributed via a regulatory news service ('This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.'). The content announces a significant corporate event (breaking ground on a new facility, expansion plans) which is generally disseminated as a news announcement rather than a formal statutory filing like a 10-K or IR. Since it is a general corporate announcement distributed through the RNS system but does not fit specific categories like ER, DIV, or MANG, the most appropriate classification is the general regulatory announcement fallback.
2023-06-13 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.